Translational breast cancer research : a journal focusing on translational research in breast cancer最新文献

筛选
英文 中文
Sacituzumab govitecan plus toripalimab compared with toripalimab plus nab-paclitaxel for first-line treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer: protocol of a multicenter, open-label, randomized phase II trial. Sacituzumab govitecan + torpalimab与torpalimab + nab-紫杉醇一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的比较:一项多中心、开放标签、随机II期试验方案
IF 1.4
Translational breast cancer research : a journal focusing on translational research in breast cancer Pub Date : 2026-10-15 eCollection Date: 2026-01-01 DOI: 10.21037/tbcr-2026-0056
Shaohua Zhang, Jianli Zhao, Xiaoling Ling, Xueli Mo, Man Li, Herui Yao, Zefei Jiang
{"title":"Sacituzumab govitecan plus toripalimab compared with toripalimab plus nab-paclitaxel for first-line treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer: protocol of a multicenter, open-label, randomized phase II trial.","authors":"Shaohua Zhang, Jianli Zhao, Xiaoling Ling, Xueli Mo, Man Li, Herui Yao, Zefei Jiang","doi":"10.21037/tbcr-2026-0056","DOIUrl":"10.21037/tbcr-2026-0056","url":null,"abstract":"<p><strong>Background: </strong>First-line therapeutic landscape for advanced triple-negative breast cancer (TNBC) has evolved significantly following recent phase III studies. In the TORCHLIGHT trial, toripalimab plus nab-paclitaxel improved progression-free survival (PFS) versus placebo combined with nab-paclitaxel in programmed death ligand 1 (PD-L1)-positive disease. In ASCENT-03, sacituzumab govitecan monotherapy demonstrated longer PFS than chemotherapy among untreated patients with advanced TNBC who were ineligible for anti-programmed cell death protein 1 (PD-1)/PD-L1 treatment. ASCENT-04/KEYNOTE-D19 reported a significant reduction in the risk of disease progression or death for sacituzumab govitecan plus pembrolizumab compared to chemotherapy plus pembrolizumab in patients with PD-L1-positive tumor. However, prospective evidence for sacituzumab govitecan plus toripalimab is lacking in a China-relevant PD-L1-positive population.</p><p><strong>Methods: </strong>This multicenter, open-label, randomized, exploratory superiority, parallel-group phase II trial (NCT07040644; protocol CO-US-979-7331) enrolls patients with treatment-naïve unresectable locally advanced or metastatic PD-L1-positive TNBC. Patients are randomly assigned in equal proportions to receive either sacituzumab govitecan at 10 mg/kg intravenously (IV; days 1 and 8) plus toripalimab at 240 mg IV (day 1) or toripalimab at 240 mg IV (day 1) plus nab-paclitaxel at 125 mg/m<sup>2</sup> IV (day 1 and 8) in a 3-week cycle. Primary endpoint is PFS assessed by investigators per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Key secondary and exploratory endpoints encompass objective response rate (ORR), duration of response (DoR), time to response (TTR), overall survival (OS), safety, and subgroup analyses, including visceral metastasis status, prior curative-setting anti-PD-(L)1 exposure, disease status, disease-free interval (DFI), and prior taxane therapy, among others.</p><p><strong>Discussion: </strong>This phase II trial is designed to evaluate the superiority of sacituzumab govitecan plus toripalimab over toripalimab plus nab-paclitaxel in a treatment setting relevant to Chinese practice. Notable design features include enrollment in China, use of toripalimab as the locally approved immune checkpoint inhibitor partner, inclusion of a broader PD-L1-positive population, and allowance for prior immune checkpoint inhibitor exposure in the curative setting. This trial may clarify the role of sacituzumab govitecan plus toripalimab in first-line PD-L1-positive advanced TNBC in China.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov, NCT07040644; URL: https://clinicaltrials.gov/study/NCT07040644.</p>","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"7 ","pages":"51"},"PeriodicalIF":1.4,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13736023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149345537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Start low to stay long: adapted dose escalation as a patient-centered strategy for adjuvant Abemaciclib. 低起点持续时间长:适应剂量递增作为辅助阿贝马昔lib的以患者为中心的策略。
IF 1.4
Translational breast cancer research : a journal focusing on translational research in breast cancer Pub Date : 2026-09-30 eCollection Date: 2026-01-01 DOI: 10.21037/tbcr-2026-0039
Stefan Lukac
{"title":"Start low to stay long: adapted dose escalation as a patient-centered strategy for adjuvant Abemaciclib.","authors":"Stefan Lukac","doi":"10.21037/tbcr-2026-0039","DOIUrl":"10.21037/tbcr-2026-0039","url":null,"abstract":"","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"7 ","pages":"54"},"PeriodicalIF":1.4,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13736028/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149345539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Precision de-escalation in HER2-enriched breast cancer: promise and pitfalls of multiomic response predictors. her2富集乳腺癌的精确降级:多组反应预测因子的希望和缺陷
IF 1.4
Translational breast cancer research : a journal focusing on translational research in breast cancer Pub Date : 2026-09-21 eCollection Date: 2026-01-01 DOI: 10.21037/tbcr-2026-0032
Jessé Lopes da Silva, Andréia Cristina de Melo
{"title":"Precision de-escalation in HER2-enriched breast cancer: promise and pitfalls of multiomic response predictors.","authors":"Jessé Lopes da Silva, Andréia Cristina de Melo","doi":"10.21037/tbcr-2026-0032","DOIUrl":"10.21037/tbcr-2026-0032","url":null,"abstract":"","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"7 ","pages":"53"},"PeriodicalIF":1.4,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13736011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149345535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Asian breast cancer: generating Asian data. 亚洲乳腺癌:生成亚洲数据。
IF 1.4
Translational breast cancer research : a journal focusing on translational research in breast cancer Pub Date : 2026-09-15 eCollection Date: 2026-01-01 DOI: 10.21037/tbcr-2026-0040
Elaine H Lim
{"title":"Asian breast cancer: generating Asian data.","authors":"Elaine H Lim","doi":"10.21037/tbcr-2026-0040","DOIUrl":"10.21037/tbcr-2026-0040","url":null,"abstract":"","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"7 ","pages":"41"},"PeriodicalIF":1.4,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13736018/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149345527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Non-malignant breast cancer-related breast edema: an overview. 非恶性乳腺癌相关乳腺水肿:综述。
IF 1.4
Translational breast cancer research : a journal focusing on translational research in breast cancer Pub Date : 2026-09-11 eCollection Date: 2026-01-01 DOI: 10.21037/tbcr-2025-1-68
Emily Deehan, Rayya Harb, Harvey Mayrovitz
{"title":"Non-malignant breast cancer-related breast edema: an overview.","authors":"Emily Deehan, Rayya Harb, Harvey Mayrovitz","doi":"10.21037/tbcr-2025-1-68","DOIUrl":"10.21037/tbcr-2025-1-68","url":null,"abstract":"<p><p>Non-malignant breast cancer-related breast edema (BCRBE) is often overlooked in the care of women with breast malignancy, yet it is estimated that up to 40% of survivors will experience this complication at some point during or after treatment. Most often resulting from impaired lymphatic drainage in the breast, arm, or chest wall, BCRBE contributes to pain, disfigurement, and reduced quality of life. This review aims to synthesize current evidence on the pathophysiology, risk factors, diagnostic approaches, and management of BCRBE to inform clinical guidelines and enhance patient outcomes. A comprehensive literature review was conducted to identify studies addressing the incidence, mechanisms, diagnostic modalities, and treatment strategies for BCRBE. Evidence indicates that both tumor-related lymphatic obstruction and treatment-induced damage from surgery, radiation, and chemotherapy contribute to fluid retention, with obesity, high body mass index, axillary dissection, and radiation to lymph nodes emerging as key risk factors. Diagnostic advances, including high-frequency ultrasound and tissue dielectric constant measurement, hold promise for early, quantitative detection. Despite its prevalence and functional impact, BCRBE remains underrecognized and poorly standardized in clinical assessment. Increasing clinician awareness, using objective measurement tools, and developing targeted prevention and rehabilitation strategies are critical to improving long-term outcomes and quality of life for breast cancer survivors.</p>","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"7 ","pages":"47"},"PeriodicalIF":1.4,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13736026/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149345534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dose optimization strategies for abemaciclib: insights from the TRADE trial. abemaciclib的剂量优化策略:来自TRADE试验的见解。
IF 1.4
Translational breast cancer research : a journal focusing on translational research in breast cancer Pub Date : 2026-09-05 eCollection Date: 2026-01-01 DOI: 10.21037/tbcr-2026-0034
Lola R Nogueira, Manuel Alva Bianchi, Eva Ciruelos
{"title":"Dose optimization strategies for abemaciclib: insights from the TRADE trial.","authors":"Lola R Nogueira, Manuel Alva Bianchi, Eva Ciruelos","doi":"10.21037/tbcr-2026-0034","DOIUrl":"10.21037/tbcr-2026-0034","url":null,"abstract":"","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"7 ","pages":"52"},"PeriodicalIF":1.4,"publicationDate":"2026-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13736025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149345531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Zero echo time versus T1-weighted gradient-recalled echo MRI of breast biopsy markers: a phantom study comparing susceptibility artifact volume and geometric dimensions. 零回声时间与t1加权梯度回忆的乳腺活检标志物的回声MRI:一项比较敏感性伪影体积和几何尺寸的假体研究。
IF 1.4
Translational breast cancer research : a journal focusing on translational research in breast cancer Pub Date : 2026-07-16 eCollection Date: 2026-01-01 DOI: 10.21037/tbcr-2026-0035
Abdullah Al Masud, Stephane R Chartier, Chidi T Nwachukwu, Ian D Langenfeld, Joshua D Trzasko, Jeffrey E Johnson, Gina K Hesley, Matthew W Urban, Christine U Lee
{"title":"Zero echo time versus T1-weighted gradient-recalled echo MRI of breast biopsy markers: a phantom study comparing susceptibility artifact volume and geometric dimensions.","authors":"Abdullah Al Masud, Stephane R Chartier, Chidi T Nwachukwu, Ian D Langenfeld, Joshua D Trzasko, Jeffrey E Johnson, Gina K Hesley, Matthew W Urban, Christine U Lee","doi":"10.21037/tbcr-2026-0035","DOIUrl":"10.21037/tbcr-2026-0035","url":null,"abstract":"<p><strong>Background: </strong>Breast biopsy markers or clips play a critical role in marking biopsy sites, cross-correlating on multi-modality imaging, guiding surgical planning, and monitoring treatment response. However, susceptibility artifacts from metallic breast biopsy markers on conventional T1-weighted (T1w) magnetic resonance imaging (MRI) can obscure adjacent tissues, precluding accurate signaling and enhancement of any residual disease, particularly following neoadjuvant chemotherapy and during targeted axillary dissection procedures. Zero echo time (ZTE) MRI, by acquiring signal before substantial phase dispersion occurs, has the potential to reduce these artifacts. The objective of this study is to compare susceptibility artifact volume and geometric dimensions of breast biopsy markers quantitatively between ZTE and T1w gradient-recalled echo (GRE) MRI acquisitions in a controlled phantom setting.</p><p><strong>Methods: </strong>Thirty-eight breast biopsy markers (37 commercially available, 1 research marker; 33 metallic, 5 non-metallic) were embedded in water-based gelatin phantoms and imaged at 1.5T using a T1w GRE sequence (Vibrant FLEX) and a ZTE sequence (oZTEo). For each sequence, susceptibility artifact volume and maximum length of the marker were quantified using adaptive thresholding with morphological refinement and compared with physical marker dimensions derived from mass and material density. Statistical analysis included Spearman correlation and Wilcoxon signed-rank tests considering P<0.05 as denoting statistical significance.</p><p><strong>Results: </strong>Compared with the physical marker volume, T1w GRE imaging produced a volumetric overestimation of 307±286 mm³ (mean ± SD), whereas ZTE imaging showed a smaller overestimation of 72±65 mm³ (P<0.001). T1w GRE imaging marker volumes were ~4-5 times larger than those from ZTE, and their corresponding marker lengths were approximately ~1.4-1.5 times greater. Image marker volumes and maximum lengths were larger than their true measurements on both MRI acquisitions. Correlation with true physical volume was weak for both T1w (ρ=0.21, P=0.22) and ZTE (ρ=0.32, P=0.053). Length correlation with physical measurement was stronger for ZTE (ρ=0.59, P<0.001) than T1w (ρ=0.28, P=0.001).</p><p><strong>Conclusions: </strong>In a controlled phantom setting, ZTE MRI demonstrated reduced susceptibility artifact volume and improved geometric agreement with true marker dimensions compared to T1w GRE. These findings warrant further investigation through prospective <i>in vivo</i> validation before clinical recommendations can be made.</p>","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"7 ","pages":"42"},"PeriodicalIF":1.4,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13736019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149345540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinicopathological analysis of breast cancer-related paraneoplastic syndrome: a case series of 6 patients. 乳腺癌相关副肿瘤综合征6例临床病理分析
IF 1.4
Translational breast cancer research : a journal focusing on translational research in breast cancer Pub Date : 2026-07-07 eCollection Date: 2026-01-01 DOI: 10.21037/tbcr-2026-0024
Yixuan Song, Junfei Yi, Ling Xu, Jingming Ye, Yinhua Liu, Ling Xin
{"title":"Clinicopathological analysis of breast cancer-related paraneoplastic syndrome: a case series of 6 patients.","authors":"Yixuan Song, Junfei Yi, Ling Xu, Jingming Ye, Yinhua Liu, Ling Xin","doi":"10.21037/tbcr-2026-0024","DOIUrl":"10.21037/tbcr-2026-0024","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer-related paraneoplastic syndrome (PNS) is rare, with an estimated incidence of approximately 0.3%. Neurological symptoms often precede the diagnosis of breast cancer; however, the clinicopathological characteristics, antibody profiles, and treatment outcomes remain incompletely defined, particularly in Asian populations. This case series from a large Chinese tertiary center aims to describe these features and highlight diagnostic challenges.</p><p><strong>Case description: </strong>Six female patients with histopathologically confirmed invasive ductal carcinoma (median age 63 years, range 53-68 years) were included. Neurological symptoms preceded breast cancer diagnosis in 4/6 patients (mean interval 3-4 months) and occurred after prior breast cancer surgery in 2/6 patients (intervals of 4 and 5 years). Phenotypes included paraneoplastic cerebellar degeneration (PCD) (2/6), brainstem encephalitis (1/6), limbic encephalitis (LE) (1/6) and mixed sensorimotor/extrapyramidal syndrome (2/6). Antibody testing revealed anti-Yo positivity in 3/6 patients, anti-Ri positivity in 2/6, and one patient had combined anti-Ri, amphiphysin, and PNMA2 antibodies; one patient tested negative. All patients underwent complete resection (R0) and received systemic oncologic therapy. After a median follow-up of 44 months, neurological outcomes were partial remission (PR) (2/6), stable disease (SD) (2/6), and progressive disease (PD) (2/6). The 5-year overall survival (OS) rate was 83.3% (one non-cancer death).</p><p><strong>Conclusions: </strong>Neurological symptoms in patients with breast cancer-related PNS frequently precede the cancer diagnosis. Anti-Yo and anti-Ri antibodies were the most detected types in this study. R0 resection combined with systemic therapy was associated with stabilization or improvement of neurological symptoms in some patients.</p>","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"7 ","pages":"49"},"PeriodicalIF":1.4,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13736022/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149345530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OneMark™ breast localisation: integrating diagnosis and surgical guidance-a narrative review. OneMark™乳房定位:整合诊断和手术指导-叙述回顾。
IF 1.4
Translational breast cancer research : a journal focusing on translational research in breast cancer Pub Date : 2026-06-30 eCollection Date: 2026-01-01 DOI: 10.21037/tbcr-2026-1-0009
Janhavi Venkataraman, Anmol Malhotra, Kefah Mokbel
{"title":"OneMark™ breast localisation: integrating diagnosis and surgical guidance-a narrative review.","authors":"Janhavi Venkataraman, Anmol Malhotra, Kefah Mokbel","doi":"10.21037/tbcr-2026-1-0009","DOIUrl":"10.21037/tbcr-2026-1-0009","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background and objective: &lt;/strong&gt;Wire-free breast localisation technologies have largely replaced wire-guided localisation and improved patient comfort and scheduling flexibility. However, most currently available systems retain a fundamental inefficiency: diagnostic biopsy and definitive surgical localisation remain separate procedural events. OneMark™ breast localisation proposes an alternative paradigm by integrating diagnostic marking and intraoperative localisation into a single step at the time of biopsy. This article evaluates whether such pathway efficiency represents a meaningful clinical advance or an unproven conceptual ambition.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This narrative review and critical appraisal examine the conceptual basis, proposed clinical applications, and pathway implications of the OneMark™ breast localisation system. Evidence was derived from publicly accessible U.S. Food and Drug Administration (FDA) clearance documentation, manufacturer-provided technical information, clinical trial registry data, and hands-on device evaluation by the senior authors using &lt;i&gt;ex vivo&lt;/i&gt; breast tissue and a recently published cadaver-based simulation study assessing detection time and visibility. This informal &lt;i&gt;ex vivo&lt;/i&gt; assessment was undertaken to familiarise the investigators with the technology and was not intended as a formal performance evaluation. No published peer-reviewed clinical outcome data are currently available.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Key content and findings: &lt;/strong&gt;OneMark™ employs a hydrogel marker containing Doppler-visible microparticles and a metallic clip, deployed at diagnostic biopsy and subsequently localised intraoperatively using surgeon-operated Doppler-based detection with visual and auditory feedback. The primary proposed advantage is pathway efficiency, eliminating the need for a separate pre-operative localisation procedure. Additional theoretical benefits include potential deployability across imaging-guided biopsy settings, including neoadjuvant systemic therapy, minimal magnetic resonance imaging (MRI) artefact, small marker size facilitating nodal deployment, and potential applicability in bracketing multifocal and extensive disease. Preliminary information suggests a lower cost compared with established wire-free localisation technologies. Preclinical cadaver-based simulation has demonstrated detection times comparable to standard biopsy clips and significantly superior visibility ratings, particularly for posterior lesions, with surgeons valuing audible Doppler feedback. However, clinical performance, reliability across anatomical sites, and oncological outcomes remain unvalidated.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;OneMark™ represents a pathway-focused innovation that challenges the conventional two-step localisation model rather than offering incremental technical refinement. While the conceptual rationale is compelling, its clinical value remains contingent on prospective clinical va","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"7 ","pages":"34"},"PeriodicalIF":1.4,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148715080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer as an evolutionary reversal-time for a paradigm shift. 癌症是范式转变的进化逆时。
IF 1.4
Translational breast cancer research : a journal focusing on translational research in breast cancer Pub Date : 2026-06-29 eCollection Date: 2026-01-01 DOI: 10.21037/tbcr-2026-1-0012
Rainer J Klement
{"title":"Cancer as an evolutionary reversal-time for a paradigm shift.","authors":"Rainer J Klement","doi":"10.21037/tbcr-2026-1-0012","DOIUrl":"10.21037/tbcr-2026-1-0012","url":null,"abstract":"","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"7 ","pages":"38"},"PeriodicalIF":1.4,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148715108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书